Supernus Pharmaceuticals (SUPN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.88
- Estimate
- $0.49
- Surprise
- +79.2%
- Revenue (period 2026-09-30)
- $226.8M
- Score at report (before → after)
- 6.6 → 6.8/10
Revenue source: xbrl.
How the report landed
Supernus Pharmaceuticals (SUPN) beat the $0.49 estimate with adjusted EPS of $0.88 — a large 79.2% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.6/10) to Sell at 6.8/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SUPN Hold at 6.8/10.
3 of the last 4 quarters beat the estimate; this quarter's +79.2% surprise compares with a +68.5% four-quarter average. Next scheduled report: 2027-02-23.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Customer: Cencora, Cardinal Health, and McKesson (76.0%)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Below 200-MA, MA slope -2.2%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $41.92
- Price target
- $51.42
- Stop
- $38.99
- Upside to target
- +22.7%
- Reward-to-risk
- 2.2:1
Risk check: trading volume is running 2.4× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-31 — shown for context, not personalized investment advice.
SUPN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.44B
- P/E (fwd)
- 9.7
- 52-week range
- $37.54–$59.68
- Off 52-week high
- 29.8%
- RSI (14)
- 46
- Volume vs avg
- 2.44×
- Score today
- 6.8/10